Short Interest in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Rises By 27.7%

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 2,350,000 shares, a growth of 27.7% from the November 30th total of 1,840,000 shares. Based on an average trading volume of 253,300 shares, the short-interest ratio is currently 9.3 days.

Analyst Ratings Changes

Several research analysts recently commented on the company. Truist Financial boosted their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. Raymond James boosted their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. Piper Sandler initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target for the company. Finally, StockNews.com lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $77.71.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the transaction, the senior vice president now owns 49,059 shares of the company’s stock, valued at $2,943,540. This represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Nikhil Lalwani sold 33,481 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the sale, the chief executive officer now owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 42,231 shares of company stock worth $2,434,286. Insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp increased its position in ANI Pharmaceuticals by 9.1% during the 3rd quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock worth $41,991,000 after purchasing an additional 58,698 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of ANI Pharmaceuticals by 3.5% during the second quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company’s stock valued at $40,132,000 after acquiring an additional 21,053 shares during the last quarter. Pacer Advisors Inc. increased its position in ANI Pharmaceuticals by 23,259.8% during the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock worth $33,907,000 after purchasing an additional 565,910 shares in the last quarter. JPMorgan Chase & Co. raised its stake in ANI Pharmaceuticals by 159.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after purchasing an additional 340,854 shares during the last quarter. Finally, Global Alpha Capital Management Ltd. lifted its holdings in ANI Pharmaceuticals by 1.8% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock valued at $32,005,000 after purchasing an additional 9,500 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Down 0.4 %

Shares of NASDAQ:ANIP opened at $54.21 on Tuesday. The firm has a 50 day simple moving average of $57.36 and a 200-day simple moving average of $59.53. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.81. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The company has a market capitalization of $1.14 billion, a PE ratio of -98.56 and a beta of 0.73.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. During the same quarter in the previous year, the business earned $1.05 earnings per share. The firm’s revenue for the quarter was up 12.5% on a year-over-year basis. On average, equities analysts predict that ANI Pharmaceuticals will post 3.87 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.